Institut Curie

Institut National De La Sante Et De La Recherche Medicale

Queen's University at Kingston

Institut National De La Sante Et De La Recherche Medicale (inserm)

Université De Versailles—saint-quentin-en-yvelines

Mnemo Therapeutics

Inserm (institut National De La Sante Et De La Recherche Medicale)

Inserm

Marc-Henri Stern

Elodie Manie

Tatiana Popova

Sebastian Amigorena

François-Clément Bidard

Alexandre Houy

Charlotte Proudhon

Amélie Kasperek

Amanda Bortolini Silveira

Joshua Waterfall

Marianne Burbage

Yago Arribas De Sandoval

Antonela Merlotti Ippolito

Benjamin Sadacca

Christopher R Mueller

Christophe R Mueller

The present disclosure relates to a method for detecting a mutation in a microsatellite sequence locus of a target fragment from a DNA sample, comprising a step of subjecting said DNA sample to a digital polymerase chain reaction (PCR) in the presence of a PCR solution comprising:

Method for detecting a mutation in a microsatellite sequence

Provided herein is a method for detecting a tumour that can be applied to cell-free samples, e.g., to cell-free detect circulating tumour DNA. The method utilizes detection of adjacent methylation signals within a single sequencing read as the basic positive tumour signal, thereby decreasing false positives. The method comprises extracting DNA from a cell-free sample obtained from a subject, bisulphite converting the DNA, amplifying regions methylated in cancer (e.g., CpG islands, CpG shores, and/or CpG shelves), generating sequencing reads, and detecting tumour signals. To increase sensitivity, biased primers designed based on bisulphite converted methylated sequences can be used. Target methylated regions can be selected from a pre-validated set according to the specific aim of the test. Absolute number, proportion, and/or distribution of tumour signals may be used for tumour detection or classification. The method is also useful in, e.g., predicting, prognosticating, and/or monitoring response to treatment, tumour load, relapse, cancer development, or risk.

Cell-free detection of methylated tumour DNA

The present disclosure relates to a method for selecting a tumor neoantigenic peptide wherein said method comprises: The present disclosure also relates to tumor neoantigenic peptide obtained according to the present method, vaccine or immunogenic composition, antibodies and immune cells derived thereof and their use in therapy of cancer.

Immunotherapy targeting tumor neoantigenic peptides

The invention relates to methods for detecting inactivation of the DNA Homologous Recombination pathway in a patient, and in particular for detecting BRCA1 inactivation.

Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors

Growing community of inventors

Paris, France

Marc-Henri Stern